Intervention

Datopotamab deruxtecan (Dato-DXd)

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting2

Common conditions10

Lead sponsors shown2

Clinical trials

3 shown

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsNCT07291037 · 2025-10-31

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNCT07825753 · 2026-09-10

NOT_YET_RECRUITING

Common conditions

Advanced or Metastatic Breast Cancer (BC)1 Advanced or Metastatic Pancreatic Adenocarcinoma1 Biliary Tract Cancer1 Colorectal Cancer1 Endometrial Cancer1 Gastric Cancer1 Metastatic Castration-resistant Prostate Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Ovarian Cancer1 Urothelial Cancer1

Leading sponsors

AstraZeneca2 Fudan University1

Trial status mix

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.